Kimberly-Clark offers bonds to help fund Tylenol maker takeover

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeInvestorKimberly-Clark offers bonds to help fund Tylenol maker takeoverKimberly-Clark Corp. is looking to help fund its pending acquisition of Kenvue Inc. as it aims to rival Unilever PLCAuthor of the article:Brian Smith and Ying LuthraTylenol is displayed for sale at a CVS Pharmacy on November 03, 2025 in Austin, Texas. Photo by Brandon Bell/Getty ImagesKimberly-Clark Corp. is selling investment-grade bonds in as many as five parts to help fund its pending acquisition of Tylenol maker Kenvue Inc.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountThe consumer-goods company is offering notes in as many as five parts with maturities of two to 10 years, according to a person with knowledge of the matter, who asked not to be identified because the details are private. Initial price discussions for the longest tenor involve a premium of about one percentage point above U.S. Treasuries, the person added.This advertisement has not loaded yet, but your article continues below.Kimberly-Clark held investor calls on Friday, amid a turbulent period for markets. Numerous companies held off on bringing high-grade bond sales last week as Treasury yields swung sharply on stronger-than-expected U.S. inflation data and worries about the artificial-intelligence trade.Canada's best source for investing news, analysis and insight.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Investor will soon be in your inbox.We encountered an issue signing you up. Please try againThe Kleenex maker’s third-quarter report is due on Nov. 5. Companies typically don’t issue bonds in the roughly two-week period before disclosing results.JPMorgan Chase & Co. provided US$7.7 billion in bridge financing late last year to help fund the acquisition. The bond sale is expected to replace that temporary borrowing facility. Other banks managing the bond sale are Citigroup Inc. and Morgan Stanley, the person said.The largely-stock acquisition, expected to close by the end of the year, is currently valued at about US$36 billion. Compensation is set to include US$6.7 billion of cash that would in part come from new debt sales, Kimberly-Clark has previously said.Kenvue has struggled financially since being spun off from Johnson & Johnson in 2023, and the company found itself battling with the Trump administration last year over the safety of its biggest product, Tylenol. Its portfolio also includes Neutrogena lotion, Listerine mouthwash, Benadryl allergy medicine and Band-Aid wound care products.Kimberly-Clark said when the combination was announced last year that buying Kenvue would create a company with US$32 billion in revenue and allow it to surpass Unilever PLC to become the second-biggest seller of health and wellness products after Procter & Gamble Co.This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.